Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: Final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 1979-1987

[No Author Info available]

Author keywords

Breast cancer; HER2 neu; Patient preference; Subcutaneous; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DERMATITIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FAINTNESS; FATIGUE; HEADACHE; HEALTH PERSONNEL ATTITUDE; HEART LEFT VENTRICLE FAILURE; HOT FLUSH; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PAIN; PATIENT ATTITUDE; PATIENT PREFERENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SATISFACTION; BREAST NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84928200454     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu364     Document Type: Article

References (19)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer 2014. V3.2014. http://www.nccn.org/(14 April 2014, date last accessed).
2. Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi7-vi23.
3. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
4. Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13: 869-878.
5. Wynne C, Ellis-Pegler RB, Waaka DS et al. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males. Cancer Chemother Pharmacol 2013; 72: 1079-1087.
6. Herceptin 600 mg/5 ml solution for injection summary of product characteristics. Roche Products Limited. http://www.medicines.org.uk/emc/medicine/28179/SPC/Herceptin+600+mg+5+ml+Solution+for+Injection/(25 March 2014, date last accessed).
7. De Cock E, Knoop A, Jakobsen EH et al. Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a timeand-motion study. Eur J Cancer 2013; 49: S432. Abstract 1955.
8. Burcombe R, Chan S, Simcock R et al. Subcutaneous trastuzumab (Herceptin®): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res 2013; 2: 133-140.
9. Pivot X, Gligorov J, Müller V et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962-970.
10. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf (31 January 2014, date last accessed).
11. The Criteria Committee for the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edition. New York: Little, Brown and Company, 1994.
12. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. 1995.
13. Pivot X, Gligorov J, Müller V et al. Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: cohort 2 of the PrefHer study; abstract P4-12-11. Cancer Res 2013; 73 (24 Suppl).
14. Fallowfield L, Jenkins V, Kilkerr J et al. Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study. Eur J Cancer 2013; 49: S385. Abstract 1759.
15. Gligorov J, Curigliano G, Müller V et al. Assessment of adverse events in patients switching between trastuzumab administration routes (subcutaneous to intravenous and intravenous to subcutaneous) in the PrefHer study. In: 9th European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 229.
16. Hegg R, Pienkowski T, Chen S-C et al. Immunogenicity of trastuzumab intravenous and subcutaneous formulations in the Phase III HannaH study; abstract 273P. Ann Oncol 2012; 23: ix95-ix115.
17. A study to compare subcutaneous versus intravenous administration of herceptin (trastuzumab) in women with HER2-positive early breast cancer. Hoffmann-La Roche; http://clinicaltrials.gov/ct2/show/NCT00950300 (14 July 2014, date last accessed).
18. Gligorov J, Azim HA, Ataseven B et al. SafeHer: A study of assisted- and selfadministered subcutaneous trastuzumab (H-SC) as adjuvant therapy in patients with early HER2-positive breast cancer (EBC). Ann Oncol 2012; 23: ix95-ix115. Abstract 315TiP.
19. De Cock E, Pan I, Sandoval M et al. Healthcare professionals' perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab. In: 9th European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 42.